Stem Cell Research
California would collect 25% of licensing revenue from treatments developed using grants from the California Institute of Regenerative Medicine under SB 771 by Sen. Sheila Kuehl (D-Los Angeles) (Bill text, 2/23).
This is part of the California Healthline Daily Edition, a summary of health policy coverage from major news organizations. Sign up for an email subscription.